Cancer screening – what you should know

submitted by: mdanderson
Download from iTunes: https://itunes.apple.com/us/podcast/cancer-screening-what-you/id43184821... The standard screenings for cancer are for breast, cervical, prostate and colon. For those in a high-risk category, lung, ovarian and liver cancer screenings may be recommended. Therese Bevers, M.D., medical director of Cancer Prevention at MD Anderson Cancer Center, discusses MD Anderson’s cancer screening recommendations and explains the conflicting cancer screening reports.

Smokers with HIV/AIDS find quitting easier with cell phone counseling

submitted by: mdanderson
Download from iTunes: https://itunes.apple.com/us/itunes-u/smokers-hiv-aids-find-quitting/id43... A smoking-cessation intervention delivered through mobile phones to smokers who are HIV/AIDS positive has a better success rate compared to standard treatment. Listen to Ellen Gritz, Ph.D., professor and chair, and Damon Vidrine, Dr.P.H., assistant professor, both in Behavioral Science at MD Anderson Cancer Center, discuss their research findings.

Stereotactic body radiation therapy (SBRT) for lung cancer

submitted by: mdanderson
Stereotactic body radiation therapy (SBRT), also called stereotactic ablative radiotherapy (SABR), is a type of radiation therapy in which a few very high doses of radiation are delivered to small, well-defined tumors. The goal is to deliver a radiation dose that is high enough to kill the cancer while minimizing exposure to surrounding healthy organs. Barbara Pool is one of six lung cancer patients per day who go through stereotactic body radiation therapy and she is the 1000th patient to...

Cancer Research for Stage 1 Lung Cancer

submitted by: mdanderson

New cancer research for stage 1 lung cancer is being investigated at The University of Texas MD Anderson Cancer Center. It’s led by Jack Roth, M.D., professor in the Department of Thoracic and Cardiovascular Surgery. This clinical trial called STARS (Stereotactic Radiation Therapy Verses Surgery) compares a new type of radiation treatment with a traditional surgery approach. Roth describes this promising new treatment and explains how lung cancer patients may get involved.

New Lung Cancer Screening Offered At MD Anderson

submitted by: mdanderson

Results from national clinical trial mobilizes a team of experts to develop Lung Cancer Screening Program. For appointment contact AskMDAnderson 877-MDA-6789 https://www2.mdanderson.org/sapp/contact/selfreferral/index.cfm

Lung Cancer - Dr. Stephen Swisher

submitted by: mdanderson

Dr. Stephen Swisher discusses lung cancer and MD Anderson's approach to treating the disease. His advice to patients with lung cancer is not to rush into a treatment program right away; instead, they should research various options and decide on the best plan, with their medical team.

The BATTLE Continues with Dr. Edward S. Kim

submitted by: mdanderson

Dr. Edward S. Kim leads the Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) program at MD Anderson and offers an update on lung cancer research. Dr. Kim also talks about the importance of continued philanthropic support for this underfunded research.

Dr. James Cox Discusses New Phase II Lung Cancer Study at the Proton Therapy Center

submitted by: mdanderson

Dr. Cox explains the outcomes of proton therapy with concurrent chemotherapy, how lung cancer patients typically tolerate treatment and what the future holds for lung cancer patients being treated with proton therapy at MD Anderson.

For more information on MD Anderson's Proton Therapy Center you can visit the website at http://mdanderson.org/proton

Path to Tumor Destruction

submitted by: mdanderson

Th17 sets off a chain of events that ends with custom-made killer T cells destroying tumors.

Helper T Cell Guides Killer Cells to Cancer

submitted by: mdanderson

Cancer manages to suppress or elude the body's immune system to survive and grow. Scientists at The University of Texas M. D. Anderson Cancer Center show this week in the journal Immunity how the helper T cell Th17 awakens the immune system to attack cancer. Senior author Chen Dong discusses the findings and their potential application for patients.